Aranesp

Type: Product
Name: Aranesp
First reported Sep 10 2014 - Updated Sep 11 2014 - 1 reports

Chemotherapy Induced Anemia Therapeutics Pipeline Review 2014 - 9 Companies & 11 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/tqbww2/chemotherapy) has announced the addition of the "Chemotherapy Induced Anemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on ... [Published Individual.com - Sep 10 2014]
First reported Sep 08 2014 - Updated Sep 09 2014 - 1 reports

Renal Anemia - Pipeline Review, H2 2014 - 22 Companies & 25 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/3xpp5q/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic ... [Published Individual.com - Sep 08 2014]
First reported Sep 08 2014 - Updated Sep 08 2014 - 1 reports

Company Update: Alexion Pharmaceuticals Inc (NASDAQ:ALXN) – Asfotase Alfa Granted Orphan Drug Designation in Japan

at 06:30 AM EDT [Business Wire] – CHESHIRE, Conn.–(BUSINESSWIRE)– Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN – News) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation (ODD) to asfotase alfa ... [Published BioSpace - Sep 08 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Amgen voluntarily recalls nine lots of anti-anemia drug

Amgen, Inc., a biotechnology company, has initiated a voluntary recall of nine packaged lots of anti-anemia drug, Aranesp, 500mcg prefilled syringes from non-US distributors, wholesalers and a number of hospital pharmacies due to the potential presence ... [Published Individual.com - Aug 28 2014]
First reported Aug 22 2014 - Updated Aug 22 2014 - 1 reports

An Analysis Of Amgen

By DoctoRx :Background : The story of Amgen 's (NASDAQ: AMGN ) first success was that it got lucky: It was seeking funding for its initial product candidates, and the money people insisted that it add one additional drug to the several that Amgen had ... [Published BioPortfolio - Aug 22 2014]
First reported Aug 14 2014 - Updated Aug 15 2014 - 4 reports

The Zacks Analyst Blog Highlights: Amgen, ANN, Citi Trends, Men's Wearhouse and Kate Spade

Today, Zacks is promoting its ''Buy'' stock recommendations. . Here are highlights from Thursday's Analyst Blog:Amgen Focus Study on Multiple Myeloma Drug FailsAmgen (Nasdaq:AMGN-Free Report) suffered a major setback when its phase III study, FOCUS (CarFilzOmib ... [Published Industrial Info Financials - Aug 15 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 2 reports

Amgen Recalls Lots of Aranesp

Amgen initiated a voluntary recall on June 26th for nine packaged lots of Aranesp (darbepoetin alfa) (500 mcg) prefilled syringes from non-U.S. distributors, wholesalers and hospital pharmacies due to the potential presence of cellulose and/or polyester ... [Published Contract Pharma - Aug 14 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 2 reports

UPDATE: Berkshire Hathaway tops $200,000; Cisco drops on results

Gainers Berkshire Hathaway Inc.(BRKA): Class A shares of Warren Buffett's Berkshire Hathaway topped $200,000 for the first time, nearly eight years after first breaking through $100,000. Kohl's Corp. (KSS): The department-store retail chain's ... [Published Morningstar.com - Aug 14 2014]
First reported Aug 13 2014 - Updated Aug 14 2014 - 3 reports

Amgen Expected To Fall As Cancer Drug Kyprolis Fails Trial

Amgen stock is expected to fall today, on news of the failure of its drug Kyprolis in clinical trials and a separate product recallClick Ticker to See live coverageAmgen, Inc. ( AMGN ) shares are expected to fall during trading today as the company announced ... [Published Bidness Etc - Aug 14 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 3 reports

MARKET SNAPSHOT : U.S. Stocks Open Higher; Wal-Mart Cuts Outlook

By Anora Mahmudova and Carla Mozee, MarketWatchNEW YORK (MarketWatch) -- U.S. stocks opened slightly higher on Thursday, but gains were capped by a larger-than-expected jump in jobless claims and a cut in outlook by Wal-Mart, the world's largest retail ... [Published 4 Traders - Aug 14 2014]
First reported Aug 13 2014 - Updated Aug 14 2014 - 7 reports

Amgen issues voluntary recall of Aranesp (500 mcg) prefilled syringes outside US

Amgen has initiated a voluntary recall on June 26, 2014 for nine packaged lots of Aranesp (darbepoetin alfa) (500 mcg) prefilled syringes from non-U.S. distributors, wholesalers and a number of hospital pharmacies due to the potential presence of cellulose ... [Published PBR - News - Aug 14 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 2 reports

Amgen Drops in After Hours on Failed Trial, Recall

Shares of Amgen (AMGN) are falling in after-hours trading after the biotech giant announced that a drug trial had failed and it had to recall one of its drugs due to visible particulates. Steve Remich Amgen said that it had recalled prefilled syringes ... [Published Street Sweeper - Aug 13 2014]
Entities: Amgen Inc, Aranesp, anemia, Drugs

Quotes

New York, NY, August 19, 2014 --( PR.com )-- Persistence Market Research (http://www.persistencemarketresearch.com) Released New Market Report on "Global Market Study on Biological Drugs: North America to Witness Highest Growth by 2020” the global biological drugs market is estimated at USD 1, 61,056.5 million in 2014 and is expected to grow at a CAGR of 10.1% from 2014 to 2020, to reach an estimated value of USD 2, 87,139.7 million in 2020."
No adverse events associated with these concerns were reported, it was stated in the news releases. FDA explains that "health implications related to particles, depending on the route of administration, would vary depending on the amount of particulate matter injected into the patient, the size of the particles, the patient's underlying medical condition, and the presence of a right-to-left cardiac shunt."
"Given our observation of an increased number of clearance zones at numerous stores, and rising amounts of excess seasonal goods on markdown as the second quarter moved along, Wal-Mart is at risk of missing second-quarter consensus earnings per share forecasts" wrote Brian Sozzi, chief equities strategist at Belus Capital Advisors, in a report earlier this week
"While it is unfortunate that the FOCUS study did not meet its primary endpoint of overall survival, we believe the results from the recent positive ASPIRE PhasePhase 3 clinical trial will be sufficient to support regulatory submissions around the world" said Pablo Cagnoni, president, Onyx Pharmaceuticals Inc

More Content

All (57) | News (50) | Reports (0) | Blogs (7) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Chemotherapy Induced Anemia Therapeutics Pipeli... [Published Individual.com - Sep 10 2014]
Renal Anemia - Pipeline Review, H2 2014 - 22 Co... [Published Individual.com - Sep 08 2014]
Company Update: Alexion Pharmaceuticals Inc (NA... [Published BioSpace - Sep 08 2014]
Pharma co shares in limelight with better Q1 pe... [Published PharmaBiz - Sep 01 2014]
Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen... [Published Jutia Group - Aug 28 2014]
Amgen voluntarily recalls nine lots of anti-ane... [Published Individual.com - Aug 28 2014]
An Analysis Of Amgen [Published BioPortfolio - Aug 22 2014]
Market Update: Amgen Inc (NASDAQ:AMGN) – Lilly ... [Published Jutia Group - Aug 21 2014]
Acute Management of Patients With Chronic Kidne... [Published U.S.Pharmacist - Aug 21 2014]
Good News For Amgen As Parathyroid Drug AMG 416... [Published BioSpace - Aug 19 2014]
Biological Drugs Market Will Reach USD 2, 87,13... [Published PR.com Press Releases - Aug 19 2014]
Manufacturing issues cause recalls for Amgen, B... [Published In-Pharmatechnologist - Aug 18 2014]
The Zacks Analyst Blog Highlights: Amgen, ANN, ... [Published Industrial Info Financials - Aug 15 2014]
Amgen Inc. (AMGN) Rose To A New High Despite Di... [Published RTTNews.com - Aug 15 2014]
Amgen, Baxter, and Cubist Issue Recalls over Pa... [Published Pharmaceutical & Medical Packaging News - Aug 15 2014]
Amgen hit as Kyprolis fails myeloma study [Published PMLive - Aug 15 2014]
Amgen Recalls Lots of Aranesp [Published Contract Pharma - Aug 14 2014]
Amgen's FOCUS Study on Multiple Myeloma Drug Ky... [Published Zacks.com - Aug 14 2014]
Most popular news headlines for Wednesday, Augu... [Published Cafepharma - Aug 14 2014]
Today's Market: Biotech And Technology Names Mo... [Published Seeking Alpha - Aug 14 2014]
Amgen recalls Aranesp syringes contaminated wit... [Published FiercePharmaManufacturing - Aug 14 2014]
UPDATE: Berkshire Hathaway tops $200,000; Cisco... [Published Morningstar.com - Aug 14 2014]
Amgen (AMGN) gains despite drug test results [Published BayStreet.ca - Aug 14 2014]
UPDATE: Plug Power rallies, GM drops on sell ra... [Published Morningstar.com - Aug 14 2014]
MARKET SNAPSHOT : U.S. Stocks Open Higher; Wal-... [Published 4 Traders - Aug 14 2014]
Lackluster Sentiment May Prevail Amid Weak Data... [Published RTTNews.com - Aug 14 2014]
MARKET SNAPSHOT: U.S. Stocks: Futures Turn Flat... [Published Nasdaq - Aug 14 2014]
MARKET SNAPSHOT: U.S. Stocks: Futures Stay Up A... [Published 4 Traders - Aug 14 2014]
Amgen Expected To Fall As Cancer Drug Kyprolis ... [Published Bidness Etc - Aug 14 2014]
U.S. stocks: Futures edge up with Wal-Mart resu... [Published Morningstar.com - Aug 14 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Biological Drugs Market Will Reach USD 2, 87,13... [Published PR.com Press Releases - Aug 19 2014]
New York, NY, August 19, 2014 --( PR.com )-- Persistence Market Research (http://www.persistencemarketresearch.com) Released New Market Report on "Global Market Study on Biological Drugs: North America to Witness Highest Growth by 2020” the global biological ...
Amgen issues voluntary recall of Aranesp (500 m... [Published PBR - News - Aug 14 2014]
Amgen has initiated a voluntary recall on June 26, 2014 for nine packaged lots of Aranesp (darbepoetin alfa) (500 mcg) prefilled syringes from non-U.S. distributors, wholesalers and a number of hospital pharmacies due to the potential presence of cellulose ...
Amgen Drops in After Hours on Failed Trial, Recall [Published BARRONS.com Stocks To Watch Today - Aug 13 2014]
Shares of Amgen (AMGN) are falling in after-hours trading after the biotech giant announced that a drug trial had failed and it had to recall one of its drugs due to visible particulates. Steve Remich Amgen said that it had recalled prefilled syringes ...
Amgen Issues Voluntary Recall of Aranesp® (darb... [Published PR Newswire: Consumer Products & Retail - Aug 13 2014]
THOUSAND OAKS, Calif., Aug. 13, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) initiated a voluntary recall on June 26, 2014 for nine packaged lots of Aranesp® (darbepoetin alfa) (500 mcg) prefilled syringes from non-U.S. distributors, wholesalers and a ...
Hetero Launches Darbepoetin Alfa, a Much Needed... [Published Marketwire - Breaking News Releases - Jun 18 2014]
HYDERABAD, INDIA--(Marketwired - Jun 18, 2014) - The Hetero Group, one of the largest manufacturers and suppliers of Active Pharmaceutical Ingredients (APIs) to the Indian pharmaceutical industry, today announced the launch of its first biosimilar product ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.